Clorox Q4 FY26: sales -2.0%, gross margin 41.3%, EPS $1.34
Clorox's fiscal fourth quarter looked ugly on the surface and mostly has an explanation underneath: revenue fell 2.0% to $1.95 billion, gross margin dropped 520 basis points, and GAAP earnings per share halved to $1.34. The view is Neutral, because most of the damage is acquisition accounting and a one-year ERP shipment swing, while the FY27 plan still implies only thin organic growth and no margin recovery.
1 · Expected vs. Actual
Free preview belowGAAP diluted EPS fell 50.0% to $1.34 from $2.68, and adjusted EPS fell 42.0% to $1.66 from $2.87, landing about a penny under the $1.67 consensus. Roughly 90 cents of the decline traces to the ERP shipment comparison, and about $0.32 of the GAAP number is GOJO acquisition and integration cost. So the miss is technical, not a demand shock.
Net sales slipped 2.0% to $1.95 billion from $1.99 billion a year earlier, with the newly acquired GOJO business adding about 10 points and organic sales falling 13.0%. That organic drop is mostly timing: roughly 13.5 points came from lapping the pull-forward orders retailers placed before the U.S. ERP switch. Strip out the ERP comparison and the quarter is steady rather than strong.
Log in to read 5 analyses a week for free
Create a free account to read 5 full earnings analyses each week — all five steps: expected vs. actual, guidance tracker, money flow, balance sheet and risks. Members get unlimited access.
Figures on this page come from the company's original SEC filings. The analysis is generated automatically and checked against validation rules, but may still contain errors or omissions. Not investment advice. · Generated 2026-09-17
Answers are based on the earnings release and the analysis above. Free accounts get 3 questions a week; members get 30 a day.